health π¬ Moderna cancer vaccine trial gives stocks a huge boost
Moderna and Merck announced that their new cancer vaccine, Intismeran Autogene, showed promise in high-risk melanoma patients. The trial involved 1,137 patients who received the vaccine alongside Merckβs Keytruda. Interim results from August 19 indicated the combined treatment reduced recurrence risk by 49% after five years. This success is a major step forward for personalized mRNA cancer therapy. Patients could potentially benefit from this vaccine as early as 2027. π¬